Cargando…

Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients

Treatment of Legionnaires’ disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as secon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Slawek, Deepika, Altshuler, Diana, Dubrovskaya, Yanina, Louie, Eddie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632526/ https://www.ncbi.nlm.nih.gov/pubmed/29026871 http://dx.doi.org/10.1093/ofid/ofx184

Ejemplares similares

Invasive Nontyphoidal Salmonella Infection in a Patient with Early-Stage Chronic Lymphocytic Leukemia
por: Slawek, Deepika, et al.
Publicado: (2017)

Outcomes of Cytomegalovirus Viremia Treatment in Critically Ill Patients With COVID-19 Infection
por: Schoninger, Scott, et al.
Publicado: (2022)

Successful Treatment of Legionnaires’ Disease with Tigecycline in an Immunocompromised Man with a Legion of Antibiotic Allergies
por: Arget, Michael, et al.
Publicado: (2019)

Stability studies with tigecycline in bacterial growth medium and impact of stabilizing agents
por: Amann, Lisa F., et al.
Publicado: (2020)

A Legionnaires’ Disease Cluster in a Private Building in Italy
por: Ricci, Maria Luisa, et al.
Publicado: (2021)

Community-acquired Legionnaires’ Disease in a Newly Constructed Apartment Building
por: Ryu, Sukhyun, et al.
Publicado: (2017)

Trends in Legionnaires’ Disease-Associated Hospitalizations, United States, 2006–2010
por: Mudali, Gayathri, et al.
Publicado: (2020)

Legionnaires’ Disease
por: Roig, J., et al.
Publicado: (2010)

Tigecycline Induced Hyperpigmentation of the Skin
por: Vandecasteele, S. J., et al.
Publicado: (2016)

Intravenous Tigecycline Facilitates Cure of Severe Clostridium difficile Infection (CDI) After Failure of Standard Therapy: A Case Report and Literature Review of Tigecycline Use in CDI
por: Navalkele, Bhagyashri D., et al.
Publicado: (2016)

Does Adjunctive Tigecycline Improve Outcomes in Severe-Complicated, Nonoperative Clostridium difficile Infection?
por: LaSalvia, Mary T., et al.
Publicado: (2017)

In Vitro Activity of Tigecycline Against Orientia tsutsugamushi
por: Lee, Sun-Myoung, et al.
Publicado: (2016)

Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
por: De Pascale, Gennaro, et al.
Publicado: (2020)

Evaluation and Treatment of Severe Rhabdomyolysis in a Patient with Legionnaires' Disease
por: Buzzard, Joshua W, et al.
Publicado: (2019)

Hyper-inflammatory profile and immunoparalysis in patients with severe Legionnaires’ disease
por: Allam, Camille, et al.
Publicado: (2023)

Legionnaires’ Disease and Travel in Europe
por: Cano, Rosa, et al.
Publicado: (2006)

Legionnaire’s disease, weather and climate
por: Sakamoto, Ryota
Publicado: (2015)

The Protean Manifestations of Legionnaires' Disease
por: Woodhead, M. A., et al.
Publicado: (1985)

Diagnostic testing for Legionnaires’ disease
por: Pierre, David M., et al.
Publicado: (2017)

Legionnaires’ Disease Mortality in Guinea Pigs Involves the p45 Mobile Genomic Element
por: Christensen, Lanette M, et al.
Publicado: (2019)

Population pharmacokinetics of tigecycline in critically ill patients
por: Luo, Xiangru, et al.
Publicado: (2023)

A case of disseminated Legionnaires’ disease: The value of metagenome next-generation sequencing in the diagnosis of Legionnaires
por: Li, Shan, et al.
Publicado: (2022)

A case of Legionnaires’ disease with severe rhabdomyolysis misdiagnosed as COVID-19
por: Sayinalp-Arslan, Basak, et al.
Publicado: (2022)

Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013
por: Hoban, Daryl J, et al.
Publicado: (2015)

Comparison of two-drug combinations, amikacin/tigecycline/imipenem and amikacin/tigecycline/clarithromycin against Mycobacteroides abscessus subsp. abscessus using the in vitro time-kill assay
por: Portell-Buj, Elena, et al.
Publicado: (2021)

Rational use of tigecycline and tigecycline blood concentration monitoring in patients with severe infection
por: Yu, Meiling, et al.
Publicado: (2023)

The mysterious illness that drove them to their knees - Ah, that Legionnaires’ disease – A historical reflection of the work in Legionnaires’ disease in New Zealand (1978 to mid-1990s) and the ‘One Health’ paradigm
por: Graham, Frances F.
Publicado: (2020)

Legionnaires’ Disease Outbreak in Murcia, Spain
por: García-Fulgueiras, Ana, et al.
Publicado: (2003)

Legionnaires' Disease with Facial Nerve Palsy
por: Basani, Shailesh R., et al.
Publicado: (2011)

Cluster of Legionnaires’ Disease in an Italian Prison
por: Fasciana, Teresa, et al.
Publicado: (2019)

Legionnaires’ disease in Europe, 2011 to 2015
por: Beauté, Julien
Publicado: (2017)

Legionnaires’ disease in the time of COVID-19
por: Cassell, Kelsie, et al.
Publicado: (2021)

Legionnaires’ Disease: Update on Diagnosis and Treatment
por: Viasus, Diego, et al.
Publicado: (2022)

A Case of Severe, Difficult-to-Diagnose Legionnaires' Disease in a Young Welder
por: McBee, Dylan B, et al.
Publicado: (2023)

Use of Carbapenems, Polymyxins, and Tigecycline in United States Children’s Hospitals, 2010–2014
por: Chiotos, Kathleen, et al.
Publicado: (2017)

Dynamics of lymphocyte subpopulations during Legionnaires' disease
por: de Jager, CPC, et al.
Publicado: (2012)

Hyponatremia and anti-diuretic hormone in Legionnaires’ disease
por: Schuetz, Philipp, et al.
Publicado: (2013)

Legionnaires’ Disease in South Africa, 2012–2014
por: Wolter, Nicole, et al.
Publicado: (2016)

The burden of legionnaires’ disease in Belgium, 2013 to 2017
por: Fastl, Christina, et al.
Publicado: (2020)

Transmission of Legionnaires’ Disease through Toilet Flushing
por: Couturier, Jeanne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ujic0kilkka84sg4i9t1182qno